The action of dipyridamole to prevent thrombosis: Practical implications for the treatment and prevention of stroke

Current Treatment Options in Cardiovascular Medicine

Volumn 8, Issue 3, 2006, Pages 221-227

  Booze, Christopher D ^b   Serebruany, Victor L ^a  

^a Osler Medical Center   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; CLOPIDOGREL; CYCLIC AMP; CYCLIC GMP; DIPYRIDAMOLE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; PLACEBO; PROTEINASE ACTIVATED RECEPTOR 1; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; ENZYME INHIBITION; HEADACHE; HIGH RISK POPULATION; HUMAN; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; RISK BENEFIT ANALYSIS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; TRANSIENT ISCHEMIC ATTACK;

EID: 33646810128     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-006-0015-9     Document Type: Article

References (38)

1. Lewandowski C, Barsan W: Treatment of acute ischemic stroke. Ann Emerg Med 2001, 37:202-216.
2. Egan RA, Biousse V: Update on ischemic stroke. Curr Opin Ophthalmol 2000, 11:395-402.
3. Albers GW: Choice of endpoints in antiplatelet trials. Which outcomes are most relevant to stroke patients? Neurology 2000, 54:1022-1028.
4. Dennis M, Bamford J, Sandercock P, Warlow C: The prognosis of transient ischemic attacks in the community. The Oxfordshire Community Stroke project. Stroke 1990, 21:848-853.
5. Petty GW, Brown RD Jr, Whisnant JP, et al.: Ischemic stroke subtypes: a population-based study of functional outcome, survival, and recurrence. Stroke 2000, 31:1062-1068.
6. Collaborative overview of randomised trials of antiplatelet therapy. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antithrombotic Trialists' Collaboration [no authors listed]. BMJ 1994, 308:81-106.
7. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Antithrombotic Trialists' Collaboration [no authors listed]. BMJ 2002, 324:71-86.
8. Eisert WG: Dipyridamole. In Platelets. Edited by Michelsen A. Philadelphia: Academic Press; 2002:803-815.
9. Lupi A, Buffon A, Finocchiaro ML, et al.: Mechanisms of adenosine-induced epicardial coronary artery dilatation. Eur Heart J 1997, 18:614-617.
10. Akinboboye OO, Idris O, Chou RL, et al.: Absolute quantitation of coronary steal induced by intravenous dipyridamole. J Am Coll Cardiol 2001, 37:109-116.
11. Picano E, Michelassi C: Chronic oral dipyridamole as a 'novel' antianginal drug: the collateral hypothesis. Cardiovasc Res 1997, 33:666-670.
12. Grant MB, Tarnuzzer RW, Caballero S, et al.: Adenosine receptor activation induces vascular endothelial growth factor in human retinal endothelial cells. Circ Res 1999, 85:699-706.
13. Gu JW, Ito BR, Sartin A, et al.: Inhibition of adenosine kinase induces expression of VEGF mRNA and protein in myocardial myoblasts. Am J Physiol Heart Circ Physiol 2000, 279:H2116-H2123.
14. Torry RJ, O'Brien DM, Connell PM, Tomanek RJ: Dipyridamole-induced capillary growth in normal and hypertrophic hearts. Am J Physiol 1992, 262:H980-H986.
15. Girolami B, Bernardi E, Prins MH, et al.: Antiplatelet therapy and other interventions after revascularisation procedures in patients with peripheral arterial disease: a meta-analysis. Eur J Vasc Endovasc Surg 2000, 19:370-380.
16. Pouleur H, Buyse M: Effects of dipyridamole in combination with anticoagulant therapy on survival and thromboembolic events in patients with prosthetic heart valves. A meta-analysis of the randomized trials. J Thorac Cardiovasc Surg 1995, 110:463-472.
17. Sacks HS, Berrier J, Nagalingham R, Chalmers TC: Dipyridamole in the treatment of angina pectoris: a meta-analysis. Thromb Res Suppl 1990, 12:35-42.
18. Heintzen MP, Heidland UE, Klimek WJ, et al.: Intracoronary dipyridamole reduces the incidence of acute coronary vessel occlusion in percutaneous transluminal coronary angioplasty - a prospective randomized study. Z Kardiol 1997, 86:961-967.
19. Heidland UE, Heintzen MP, Michel CJ, Strauer BE: Adjunctive intracoronary dipyridamole in the interventional treatment of small coronary arteries: a prospectively randomized trial. Am Heart J 2000, 139:1039-1045.
20. Bult H, Fret HR, Jordaens FH, Herman AG: Dipyridamole potentiates platelet inhibition by nitric oxide. Thromb Haemost 1991, 66:343-349.
21. Colli S, Tremoli E: Multiple effects of dipyridamole on neutrophils and mononuclear leukocytes: adenosine-dependent and adenosine-independent mechanisms. J Lab Clin Med 1991, 118:136-145.
22. Olinde JG, Zibari GB, Brown MF, et al.: Persantine attenuates hemorrhagic shock-induced P-selectin expression. Am Surg 2000, 66:1093-1097; discussion 1097-1098.
23. Serebruany V, Malinin A, Ziai W, et al.: Dipyridamole decreases protease-activated receptor and annexin-V binding on platelets of poststroke patients with aspirin nonresponsiveness. Cerebrovasc Dis 2005, 21:98-105.
24. Persantine Aspirin Trial in cerebral ischemia. Part II: Endpoint results. The American-Canadian Co-Operative Study group [no authors listed]. Stroke 1985, 16:406-415.
25. Muller TH, Su CA, Weisenberger H, et al.: Dipyridamole alone or combined with low-dose acetylsalicylic acid inhibits platelet aggregation in human whole blood ex vivo. Br J Clin Pharmacol 1990, 30:179-186.
26. European Stroke Prevention Study. ESPS Group [no authors listed]. Stroke 1990, 21:1122-1130.
27. Diener HC, Cunha L, Forbes C, et al.: European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996, 143:1-13.
28. Saniabadi AR, Fisher TC, McLaren M, et al.: Effect of dipyridamole alone and in combination with aspirin on whole blood platelet aggregation, PGI2 generation, and red cell deformability ex vivo in man. Cardiovasc Res 1991, 25:177-183.
29. Serebruany VL, Malinin AI, Sane DC, et al.: Magnitude and time course of platelet inhibition with Aggrenox and aspirin in patients after ischemic stroke. The AGgrenox versus Aspirin Therapy Evaluation (AGATE) Trial. Eur J Pharmacol 2004, 499:315-324.
30. Serebruany VL, Gurbel PA, O'Connor CM: Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharm Res 2001, 43:453-462.
31. Serebruany VL, Malinin AI, Lowry DR, et al.: Platelet inhibition by valsartan and valeryl 4-hydroxy valsartan: a possible missing link to explain benefits of angiotensin ii receptor blockers in patients after acute vascular events. J Cardiovasc Pharmacol 2004, 43:677-684.
32. Serebruany VL, Malinin AI, O'Connor CM, Gurbel PA: Effects of roxifiban on platelet aggregation and major receptor expression in patients with coronary artery disease. For the Roxifiban Oral Compound Kynetics Evaluation Trial-I (The ROCKET-I Platelet Substudy). Am Heart J 2003, 146:91-98.
33. Serebruany VL, Steinhubl SR, Berger PB, et al.: Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol 2005, 45:246-251.
34. Management of patients with acute coronary syndromes in the united states by platelet glycoprotein IIb/IIIa inhibition. Insights from the Platelet glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial. PURSUIT Trial Investigators [no authors listed]. Circulation 2000, 102:1093-1100.
35. Miller JM, Smalling R, Ohman EM, et al.: Effectiveness of early coronary angioplasty and abciximab for failed thrombolysis (reteplase or alteplase) during acute myocardial infarction (results from the GUSTO-III trial). Global Use of Strategies To Open occluded coronary arteries. Am J Cardiol 1999, 84:779-784.
36. Serebruany VL, Malinin AI, Sane DC: Risk of bleeding complications with antiplatelet agents: a meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am J Hematol 2004, 75:40-47.
37. Serebruany VL, Malinin AI, Berger PB, et al.: The risk of bleeding complications after different doses of aspirin: A post-hoc analysis of 192,036 patients enrolled in 31 randomized controlled trials. Am J Cardiol 2005, 95:1218-1222.
38. Boysen G: Bleeding complications in secondary stroke prevention. J Intern Med 1999, 246:239-245.